Skip to main content

Table 2 Virologic, serologic and biochemical response at week 48

From: Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients

  Baseline Week 24 Week 48 Total P
Mean HBV DNA (log10 IU/mL) 6.61 1.72 1.49 5.12↓ 0.559
 ETV (n = 105) 6.56 1.80 1.55 5.01↓  
 TDF (n = 105) 6.66 1.64 1.44 5.22↓  
HBV DNA negativity by PCR     161(76.7%) 0.192
 ETV (n = 105)   58 (55.2%) 76 (72.4%)   
 TDF (n = 105)   56 (53.3%) 85 (81.0%)   
HBeAg loss/seroconversion     18 (14.9%) 0.452
 ETV (n = 58)    7 (12.1%)   
 TDF (n = 63)    11 (17.5%)   
Biochemical response     150 (81.5%) 0.647
 ETV (n = 92)    77 (83.7%)   
 TDF (n = 92)    73 (79.3%)   
  1. Data are expressed mean or number
  2. ETV entecavir, HBeAg hepatitis B e antigen, HBV hepatitis B virus, TDF tenofovir